Evidence map›Paper›PMID 41036155›Full record

ArticleClinical case reports2025

Two Cases of Heterozygous Familial Hypercholesterolemia in Children Effectively Managed With Pitavastatin and Ezetimibe Combination Therapy.

Katsufumi Nishioka, Sonoko Kondo, Kanako Irie, Takeo Kondo, Takashi Iwase, Ryosuke Tani, Tomoko Inoue, Keiji Matsunaga, Tetsuo Minamino, Takashi Kusaka

Abstract read
In one paragraph

Article in Clinical case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Katsufumi NishiokaDepartment of Pediatrics, Faculty of Medicine Kagawa University Miki Kagawa Japan.
Sonoko KondoDepartment of Pediatrics, Faculty of Medicine Kagawa University Miki Kagawa Japan.ORCID https://orcid.org/0009-0005-9671-4300
Kanako IrieDepartment of Pediatrics, Faculty of Medicine Kagawa University Miki Kagawa Japan.
Takeo KondoDepartment of Pediatrics, Faculty of Medicine Kagawa University Miki Kagawa Japan.
Takashi IwaseDepartment of Pediatrics, Faculty of Medicine Kagawa University Miki Kagawa Japan.
Ryosuke TaniDepartment of Cardiorenal and Cerebrovascular Medicine, Faculty of Medicine Kagawa University Miki Kagawa Japan.
Tomoko InoueDepartment of Cardiorenal and Cerebrovascular Medicine, Faculty of Medicine Kagawa University Miki Kagawa Japan.
Keiji MatsunagaDepartment of Cardiorenal and Cerebrovascular Medicine, Faculty of Medicine Kagawa University Miki Kagawa Japan.
Tetsuo MinaminoDepartment of Cardiorenal and Cerebrovascular Medicine, Faculty of Medicine Kagawa University Miki Kagawa Japan.
Takashi KusakaDepartment of Pediatrics, Faculty of Medicine Kagawa University Miki Kagawa Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Heterozygous familial hypercholesterolemia (HeFH) strongly predisposes individuals to atherosclerosis, including coronary artery disease, leading to death from cardiovascular diseases in > 60% of untreated cases. Appropriate intervention from childhood is necessary. In Japan, only pitavastatin is approved for pediatric FH. A poor response to statins makes treatment challenging; optimal intervention may require combination therapy.

Indexed as

childezetimibefamilial hypercholesterolemiapitavastatin

Identifiers

PMID41036155
PMCPMC12479202

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.